Events
-
ENDO 2026: Women’s thyroid cancer risk may be linked to reproductive lifespan and hormone therapy
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
ASCO 2026: CAPTURE trial delivers learnings for metastatic breast cancer treatment
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
ASCO 2026: Lancet Commission predict shortfall of 100 million cancer care workers by 2050
-
-
ASCO 2026: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma
-
-
-
More than 10,000 job losses, billions in lost revenue: coronavirus will hit Australia’s research capacity harder than the GFC
Frank Larkins, University of Melbourne and Kylie Walker, Australian National University Australia’s researchers have answered…
Breast cancer ‘signature’ predicts response to new drug class
Melbourne researchers have developed a new way to pinpoint which breast cancers will respond to…
Killing ‘sleeper cells’ may enhance breast cancer therapy
The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive (ER+) breast cancer…
Research Check: do most melanoma patients have fewer than 20 moles?
H. Peter Soyer, The University of Queensland and Richard Sturm, The University of Queensland The sooner cancer is diagnosed, the…
JOIN THE ONCOLOGY NETWORK
If you would like even more free news articles, access to our exclusive HCP only content including the latest podcasts from The Oncology Podcast and our Industry Partner Podcasts (including links to all papers and show notes), along with all our other resources, head over to The Oncology Network and sign up - FREE forever for HCPs only.